The post-GLP-1 phase refers to the period during tapering or within the first 6 months after stopping GLP-1 therapy.

During this time, the body transitions away from:

• Appetite suppression
• Slower gastric emptying
• Enhanced insulin sensitivity
• Pharmacologically supported weight regulation

This creates a rebound-prone physiological state, where metabolic and behavioral adaptations may reverse.

Why this phase is high risk

GLP-1 medications actively support appetite control and metabolic regulation. When they are removed:

• Hunger signals increase
• Caloric intake often rises
• Energy expenditure may remain reduced
• Prior metabolic tendencies can re-emerge

Clinical observations show that a significant proportion of lost weight (up to ~40%) may be regained within the first 6 months, alongside deterioration in metabolic markers.

Because of this, the post-GLP-1 phase requires active monitoring, not passive observation.

What biomarkers matter after stopping GLP-1

1. Glycemic and insulin markers

After discontinuation:

• Insulin sensitivity may decrease
• Glucose levels may rise

Tracking helps detect early metabolic regression.

2. Lipid profile

Common trends include:

• Rising triglycerides
• Worsening LDL/HDL balance

These changes may occur gradually but are clinically significant.

3. Weight trajectory (trend-based)

While not a blood biomarker, weight trend is critical:

• Early regain patterns can predict long-term outcomes
• Small increases early often accelerate without intervention

4. Liver function and NAFLD markers

As metabolic health regresses:

• Liver fat may re-accumulate
• ALT / AST may trend upward

5. Hormonal markers (e.g., insulin, testosterone)

Changes in energy balance and body composition may affect:

• Insulin dynamics
• Hormonal regulation

6. Nutritional and protein status

If eating patterns shift toward:

• Higher calorie, lower nutrient intake

There may be a decline in:

• Protein adequacy
• Micronutrient status

What changes are most common after discontinuation

1. Increased appetite and reduced satiety. The most immediate change: hunger signals return and portion sizes increase
2. Weight regain, which is often driven by: increased intake and persistent metabolic adaptation (lower energy expenditure)
3. Worsening glycemic control: particularly in individuals with prior insulin resistance.
4. Lipid rebound: Triglycerides and cholesterol may gradually increase.
5. Behavioral drift: structured eating patterns during therapy may become less consistent.

Why monitoring is critical in this phase

Unlike earlier phases, this stage is not about adaptation to a drug—but adaptation without it.

Without monitoring:

• Early negative trends may go unnoticed
• Weight regain may accelerate
• Metabolic deterioration may become harder to reverse

Biomarkers allow for:

• Early detection of regression
• Timely intervention
• More sustainable long-term outcomes

How to reduce rebound risk

• Maintain structured eating: prioritize protein and meal consistency
• Continue physical activity: especially resistance training to preserve lean mass
• Monitor trends early: small changes are easier to correct than large ones
• Avoid “all-or-nothing” shifts: gradual transition off therapy is preferable to abrupt discontinuation when possible

How often should you monitor

Because this is a high-risk transition period:

• Monthly monitoring for the first ~6 months after stopping GLP-1
• Focus on biomarker trends and weight trajectory
• Continued symptom and behavioral awareness

Key takeaway

The post-GLP-1 phase is a rebound-sensitive period.

A biomarker-driven approach allows for early detection of metabolic drift and supports long-term weight and metabolic stability after therapy ends.

Where can I learn more?

GLP-1 analog therapy and hemoglobin levels: Insights from a retrospective study – PMC

https://www.healthline.com/health/drugs/ozempic-blood-test

https://www.mayoclinic.org/drugs-supplements/teriparatide-subcutaneous-route/description/drg-20066280

The long-term phase begins after 16 weeks of treatment, once a stable and tolerated GLP-1 dose has been reached.

At this stage:

• Appetite suppression becomes more predictable
• Weight loss slows and stabilizes
• The body reaches a more consistent metabolic state

The focus shifts from short-term adaptation to long-term preservation, optimization, and safety.

How this phase differs from the early phase

While both phases are biomarker-driven, the purpose of monitoring changes:

In this phase, biomarkers are interpreted over time and trends, not in isolation.

Which biomarkers matter most long-term

1. Lipid profile

GLP-1 therapy often improves:

• Triglycerides
• LDL and HDL balance

Monitoring confirms cardiometabolic benefit and trajectory.

2. Glycemic and insulin markers

Long-term improvements in:

• Glucose regulation
• Insulin sensitivity

These markers help assess sustained metabolic health.

3. Liver function and NAFLD markers

GLP-1 therapy is associated with reduced liver fat, making it important to track:

• ALT / AST trends
• Broader liver health markers

4. Hormonal balance

Weight loss and reduced caloric intake can influence:

• Testosterone and Estradiole levels
• Energy, recovery, and body composition

Monitoring ensures hormonal preservation during fat loss.

5. Micronutrient status

Sustained appetite suppression may reduce intake of key nutrients:

• Vitamin B12
• Iron
• Vitamin D

Deficiencies may develop gradually and require proactive monitoring.

6. Protein status and muscle preservation (indirect markers)

Long-term caloric restriction increases risk of:

• Lean mass loss
• Reduced metabolic rate

Biomarkers and clinical context help assess adequacy of:

• Protein intake
• Overall nutritional status

What risks emerge over time

• Muscle loss (sarcopenia): without adequate protein and resistance training, weight loss may include lean mass.
• Micronutrient deficiencies: gradual reductions in intake can lead to deficiencies that are not immediately symptomatic.
• Hormonal suppression: prolonged caloric deficit may affect endocrine balance, particularly testosterone.
• Gallbladder risk is still high. Ongoing weight loss continues to carry risk of: gallstone formation and intermittent biliary symptoms
• Plateaus or suboptimal response. In some individuals: weight loss may plateau or metabolic improvements may stabilize early

Biomarkers help distinguish true plateau vs. modifiable factors.

How to optimize outcomes on GLP-1

• Preserve lean mass: prioritize protein intake and incorporate resistance training
• Maintain nutrient sufficiency: monitor and supplement where needed
• Track trends, not single results: longitudinal data is more clinically meaningfu
• Align lifestyle with treatment: sleep, movement, and diet remain essential for sustained benefit

How often should you monitor

Because this phase is more stable:

• Quarterly (every ~3 months) biomarker testing
• Trend-based interpretation over time
• Continued symptom awareness as supporting context

Key takeaway

The long-term phase of GLP-1 therapy is about optimization and preservation.

It remains biomarker-driven, but shifts focus toward sustaining metabolic improvements, protecting muscle and hormonal health, and preventing slow-developing deficiencies.

Where can I read more?

GLP-1 analog therapy and hemoglobin levels: Insights from a retrospective study – PMC

https://www.healthline.com/health/drugs/ozempic-blood-test

https://www.mayoclinic.org/drugs-supplements/teriparatide-subcutaneous-route/description/drg-20066280

The early phase (commonly the first ~16 weeks) refers to the period of dose escalation and physiological adaptation to GLP-1 receptor agonists (such as semaglutide, liraglutide, or tirzepatide).

During this phase, the body is adjusting to:

• Slower gastric emptying
• Reduced appetite and caloric intake
• Changes in hydration and electrolyte balance
• Rapid metabolic shifts

This makes it the most dynamic phase of treatment, where both tolerance and early metabolic response need to be monitored closely.

Why monitoring is different in this phase

While both early and later phases rely on biomarkers, the type and purpose of monitoring differ.

In the early phase:

• Biomarkers are used to detect acute physiological stress and tolerance issues
• Changes can occur rapidly and non-linearly
• Symptom context is still important for interpretation

Which biomarkers matter most early on

1. Electrolytes and hydration markers

Reduced food and fluid intake can quickly affect:

• Total Protein
• Kidney function markers (e.g., creatinine trends)

These help detect early dehydration or imbalance.

2. Liver enzymes and metabolic stress

Rapid weight loss and metabolic shifts may transiently affect:

• ALT / AST
• Markers associated with liver fat mobilization

3. Lipid profile (especially triglycerides)

Triglycerides are particularly important early on:

• Elevated levels increase pancreatitis risk
• Rapid metabolic changes may initially destabilize lipid levels

4. Glycemic markers

GLP-1 therapy rapidly affects glucose regulation:

• % HbA1c
• C-Peptide

These help assess early metabolic response and detect excessive drops in intake or imbalance.

5. Nutritional status indicators (early trends)

Even early in treatment, reduced intake may begin to impact:

• Ferritin
• Vitamin D

What symptoms still play a role

Although this is a biomarker-driven phase, symptoms provide essential context for interpreting early changes.

Important symptoms include:

• Persistent nausea or vomiting
• Inability to maintain hydration
• Abdominal pain (especially severe or radiating)
• Dizziness or weakness
• Right upper abdominal discomfort (gallbladder-related)

Symptoms help determine whether biomarker changes reflect:

• Normal adaptation

  or

• Emerging intolerance or risk

Key risks in the early phase

• Gastrointestinal intolerance: driven by delayed gastric emptying and central appetite effects.
• Dehydration and electrolyte imbalance: often due to reduced intake rather than direct drug effect.
• Under-eating and rapid caloric deficit: can begin affecting metabolic stability and lean mass early.
• Gallbladder stress: triggered by rapid weight loss and fat mobilization, rather than routine enzyme screening alone

How to support your body during this phase

• Maintain hydration: fluid intake should be intentional, not appetite-driven.
• Prioritize protein and nutrient density: even small meals should be nutritionally meaningful.
• Monitor both labs and symptoms together: neither should be interpreted in isolation.
• Avoid aggressive dose escalation: tolerance should guide progression.

How often should you monitor

Because this phase is dynamic:

• Monthly biomarker monitoring during the first 16 weeks
• Ongoing symptom tracking for context
• Additional testing if abnormalities or symptoms arise

Key takeaway

The early phase of GLP-1 therapy is about safe adaptation.

It remains biomarker-driven, but focuses on short-term physiological stability, tolerance, and early metabolic shifts, rather than long-term optimization.

Where can I read more?

GLP-1 analog therapy and hemoglobin levels: Insights from a retrospective study – PMC

https://www.healthline.com/health/drugs/ozempic-blood-test

https://www.mayoclinic.org/drugs-supplements/teriparatide-subcutaneous-route/description/drg-20066280

Pre-GLP-1 baseline testing is a structured health assessment performed before starting GLP-1 receptor agonist medications (such as semaglutide, liraglutide, or tirzepatide).

Its purpose is to establish a true cardiometabolic and clinical reference point before treatment begins, allowing for accurate interpretation of metabolic changes over time.

This includes identifying underlying issues such as:

• Thyroid dysfunction
• Lipid abnormalities
• Testosterone imbalance
• Early fatty liver disease (NAFLD)
• Insulin resistance patterns

Without a baseline, it becomes difficult to distinguish medication effects from pre-existing metabolic or pharmacological influences.

Why a baseline matters before starting GLP-1 therapy

GLP-1 medications can significantly affect:

• Weight and appetite regulation
• Glucose metabolism
• Lipid profiles
• Liver fat content
• Gastrointestinal function and drug absorption

Because these changes can occur rapidly, starting therapy without baseline data reduces interpretability of outcomes.

A structured baseline helps:

• Identify pre-existing metabolic risk
• Detect hidden endocrine or lipid abnormalities
• Establish a clear comparison point for treatment response
• Improve long-term safety and tracking accuracy

What should be assessed before starting GLP-1s?

A comprehensive Pre-GLP-1 baseline focuses on cardiometabolic, endocrine, and pharmacological safety factors:

1. Thyroid function

Thyroid hormones regulate metabolic rate and energy balance. Undiagnosed dysfunction can influence weight response and symptom interpretation.

2. Lipid profile

Elevated triglycerides and dyslipidemia are key metabolic risk factors and relevant for overall cardiometabolic health and pancreatitis risk stratification.

3. Liver health (NAFLD risk)

Non-alcoholic fatty liver disease is closely linked to insulin resistance and may improve significantly with GLP-1 therapy.

4. Sex hormones

Hormonal imbalance can affect fat distribution, energy levels, and metabolic adaptation.

5. Glycemic and insulin markers

These define baseline insulin resistance and expected metabolic response trajectory.

6. Reproductive and pregnancy status

Pregnancy status must be assessed before starting GLP-1 therapy, as these medications are not recommended during pregnancy due to insufficient human safety data and potential fetal risk.

7. Current Medications and Interaction Risk

Before starting GLP-1 receptor agonist therapy, you should inform their clinician of all medications they are taking, including prescription drugs, over-the-counter treatments, and supplements. This is important because GLP-1 medications slow gastric emptying and intestinal transit, which can affect how other drugs are absorbed and tolerated.

Special attention should be paid to the following categories:

• Medications with narrow therapeutic windows (where small changes in blood levels can have significant effects)

Examples: warfarin, levothyroxine, lithium

• Medications requiring consistent absorption or timing (where altered absorption may reduce efficacy or stability)

Examples: levothyroxine, oral contraceptives, tacrolimus

• Diabetes medications that increase hypoglycemia risk when combined

Examples: insulin, sulfonylureas such as glipizide or gliclazide

• Medications that affect gastrointestinal motility or are affected by it

Examples: metoclopramide, loperamide, erythromycin

• Patients on complex polypharmacy or unstable regimens (e.g., multiple cardiovascular, psychiatric, or endocrine medications with frequent dose adjustments)

Examples: antidepressants (sertraline, amitriptyline), antiepileptics (valproate, carbamazepine), antihypertensives (amlodipine, beta-blockers such as bisoprolol)

Because GLP-1 therapy can slow digestion, it may alter the timing, absorption, and overall effectiveness of co-administered medications, particularly during dose initiation and escalation. Careful monitoring and individualized dose adjustments may therefore be required under medical supervision.

When NOT to start GLP-1 medications

GLP-1 therapy should be avoided or delayed in the presence of certain clinical conditions.

You should be made aware of these risks and inform your physician if you have any of the following conditions before starting GLP-1 treatment:

• Active or suspected pancreatitis
• Previous history of pancreatitis
• Unexplained persistent or severe abdominal symptoms
• Untreated or symptomatic gallbladder disease
• Previous history of gallbladder disease
• Severe gastrointestinal disorders affecting gastric emptying
• Uncontrolled endocrine disorders requiring stabilization
• Pregnancy or active attempts to conceive without medical supervision

  GLP-1 receptor agonists are not recommended during pregnancy. Treatment should be avoided or discontinued if pregnancy occurs, with appropriate clinical follow-up.

• History of contraindicated thyroid malignancy (e.g., medullary thyroid carcinoma or MEN2)
• Severe malnutrition or eating disorders requiring primary stabilization
• Unstable or high-risk medication regimens where absorption or dosing cannot yet be safely predicted

In these cases, initiating therapy without addressing underlying risks may reduce safety and clinical clarity.

How baseline and Day 0 testing works

A structured Pre-GLP-1 protocol typically involves two steps:

1. Baseline assessment (pre-screening phase)

• Identifies metabolic, endocrine, reproductive, and medication-related risks
• Establishes eligibility and risk stratification

2. Day 0 (treatment initiation point)

• Re-confirms baseline status immediately before first dose
• Ensures stability of medication and clinical variables
• Locks in reference values for longitudinal tracking

This ensures that all subsequent changes can be attributed to therapy and lifestyle rather than pre-existing variability.

Why this matters clinically

Without structured baseline assessment, GLP-1 response interpretation becomes less precise. For example:

• Weight loss may mask underlying thyroid dysfunction
• Lipid improvements may reflect baseline fluctuation rather than treatment effect
• Gastrointestinal symptoms may be misattributed to medication instead of pre-existing disease or drug interactions
• Medication side effects may be misinterpreted if absorption changes are not accounted for

A structured baseline ensures clarity, safety, and meaningful long-term metabolic insight.

Where can I read more?

GLP-1 analog therapy and hemoglobin levels: Insights from a retrospective study – PMC

https://www.healthline.com/health/drugs/ozempic-blood-test

https://www.mayoclinic.org/drugs-supplements/teriparatide-subcutaneous-route/description/drg-20066280

Amylase and lipase are digestive enzymes produced by the pancreas.

• Amylase helps break down carbohydrates
• Lipase helps break down fats

In clinical settings, these enzymes are often measured when acute pancreatitis is suspected, as they can rise during active pancreatic inflammation.

However, their role is primarily diagnostic during an acute event, rather than predictive of future risk.

Why we do not rely on amylase and lipase for GLP-1 pancreatitis risk screening?

GLP-1 receptor agonists (such as semaglutide and similar medications) have been associated with pancreatitis. Because of this, monitoring pancreatic safety is important, but enzyme testing alone is not an effective screening tool for risk prediction.

There are several reasons for this:

• They rise acutely after inflammation beginsAmylase and lipase typically increase once pancreatic injury is already underway, not before symptoms develop.
• They are not specific for GLP-1–related riskElevated levels may occur due to gallstones, gastrointestinal conditions, kidney dysfunction, or other non-pancreatic causes.
• They may remain normal in some clinically significant casesParticularly in early, mild, or atypical presentations, enzyme levels can be misleadingly normal.

Because of this, relying solely on these biomarkers may miss early warning signs or overestimate risk in unrelated conditions.

How pancreatitis risk is assessed in GLP-1 users

Instead of routine enzyme testing, pancreatitis risk is better evaluated using a symptom- and risk-factor–based approach, especially in individuals using GLP-1 therapy.

This is why our program includes:

• Structured symptom questionnaires
• Medical and medication history review
• Metabolic risk profiling
• Identification of known pancreatitis risk factors

Key risk factors may include:

• History of gallstones
• High triglycerides
• Excess alcohol intake
• Prior episodes of unexplained abdominal pain
• Rapid metabolic changes or weight loss
• Concurrent medications affecting pancreatic or biliary function

This approach focuses on early identification of clinical risk patterns rather than late biochemical changes.

What symptoms are important to monitor?

Important symptoms to monitor include:

• Persistent upper abdominal pain (especially central)
• Pain that radiates to the back
• Nausea or vomiting that does not resolve
• Pain that worsens after eating
• Abdominal tenderness or bloating
• Sudden loss of appetite with gastrointestinal discomfort

If these symptoms are severe, persistent, or worsening, medical evaluation is necessary.

How to reduce pancreatitis risk while on GLP-1 therapy

For individuals using GLP-1 medications, risk reduction focuses on supporting overall pancreatic and metabolic health:

• Avoid or limit alcohol intake
• Maintain healthy triglyceride levels through diet, exercise and regular monitoring
• Follow appropriate dose escalation protocols for GLP-1 therapy
• Manage gallstone risk where relevant (especially during rapid weight loss)
• Maintain hydration and balanced nutrition during appetite suppression
• Report persistent gastrointestinal symptoms early rather than waiting for lab changes

These strategies help reduce the likelihood of pancreatic stress during treatment.

Where can I learn more?

If you want to better understand pancreatitis risk in the context of GLP-1 medications, it is useful to explore our referenced literature:

• https://www.ccjm.org/content/ccjom/92/8/483.full.pdf
• https://www.endocrinepractice.org/article/S1530-891X(25)00749-9/fulltext
• https://www.diabetesresearchclinicalpractice.com/article/S0168-8227(24)00716-2/fulltext

GLP-1 receptor agonists produce weight loss primarily through central appetite suppression and sustained reduction in caloric intake. While commonly described as having a broad range of “side effects,” most observed clinical changes are not due to direct pharmacologic toxicity. Instead, they represent predictable physiological adaptations to chronic negative energy balance.

As caloric intake decreases, the body transitions into an energy-conserving state. This affects skeletal muscle maintenance, micronutrient status, hydration balance, endocrine signaling, and cognitive energy availability. These changes occur gradually and are best understood through longitudinal biomarker trends rather than isolated laboratory abnormalities.

Clinical interpretation should therefore focus on distinguishing adaptive changes from emerging deficiency states, particularly in patients experiencing rapid or sustained weight loss.

Energy Restriction and Global Metabolic Adaptation

The primary mechanism of GLP-1 therapy is hypothalamic appetite suppression, resulting in sustained caloric deficit. This drives systemic metabolic adaptation, including preferential fat oxidation, reduced glycogen storage, and decreased anabolic signaling.

Biomarkers

• Body weight: Integrative marker of cumulative energy balance. Rapid declines may indicate excessive caloric restriction or inadequate nutritional compensation.
• Body composition: Differentiates fat mass reduction from lean mass loss. Disproportionate lean mass reduction suggests insufficient protein intake or excessive energy deficit.
• Albumin: Reflects long-term protein-energy status. It is a late and non-specific marker influenced by inflammation, hydration status, and hepatic function.

Fatigue and Reduced Energy Availability

Fatigue in GLP-1 therapy is most commonly a consequence of sustained caloric deficit rather than a direct pharmacologic effect. Reduced energy intake leads to lower glycogen reserves and reduced metabolic substrate availability, which can manifest as reduced stamina, slower recovery, and generalized low energy.

Biomarkers

• C-peptide: Reflects endogenous insulin secretion and overall beta-cell activity. In this context, it is used as a proxy for physiologic metabolic drive. Lower or declining values may be consistent with reduced nutrient stimulation and overall lower anabolic signaling during sustained caloric restriction.
• HbA1c: Reflects long-term glycemic exposure and overall metabolic stability. It does not capture acute fatigue but helps contextualize systemic metabolic control during weight loss.
• Albumin: May decline in prolonged energy restriction but is a late and non-specific marker of nutritional status.
• Body weight: Provides the most practical contextual indicator of energy deficit severity and duration.

Cognitive Effects and Energy Substrate Limitation

Cognitive symptoms such as reduced concentration, mental fatigue, or “brain fog” are generally linked to reduced systemic energy availability rather than direct central nervous system effects of GLP-1 signaling.

Biomarkers

• C-peptide: Reflects endogenous insulin production and overall metabolic signaling capacity. In this context, lower values may indicate reduced anabolic and energy-replete signaling states during sustained caloric restriction.
• HbA1c: Provides long-term glycemic context but does not reflect acute cognitive energy availability.

Lean Mass Loss and Protein-Energy Imbalance

Lean mass reduction occurs when protein intake is insufficient to match energy deficit. This is a clinically important concern during GLP-1–induced weight loss, particularly in cases of rapid or sustained reduction in body weight.

Biomarkers

• Body composition: Gold standard for assessing lean mass changes. A disproportionate decline in lean mass relative to fat mass indicates muscle catabolism.
• Total protein: Reflects circulating protein availability but lacks sensitivity for early muscle loss.
• Albumin: Late marker of protein-energy deficiency; non-specific and influenced by multiple physiological states.

Micronutrient Deficiency States

Reduced caloric intake and smaller meal volume can lead to progressive micronutrient depletion over months, particularly in iron, vitamin B12, and folate.

Biomarkers

• Ferritin: Primary indicator of iron stores. Declining levels precede anemia and reflect early depletion.
• Iron studies (serum iron, TIBC, transferrin saturation): Assess functional iron availability. Low transferrin saturation with low ferritin confirms iron deficiency.
• Vitamin B12: Essential for hematologic and neurologic function. Deficiency develops gradually and may precede clinical symptoms.
• Folate: Required for DNA synthesis and erythropoiesis. Low levels contribute to macrocytic anemia and fatigue.

Vitamin D Insufficiency

Vitamin D status may decline during GLP-1 therapy due to reduced dietary intake and altered adipose tissue distribution affecting storage dynamics.

Biomarkers

• 25-hydroxyvitamin D: Primary circulating form and most reliable marker of vitamin D status. Decline reflects reduced intake or altered bioavailability during weight loss.

Hydration Status and Renal Function Changes

Reduced appetite and gastrointestinal side effects frequently lead to decreased fluid intake, resulting in mild dehydration and hemoconcentration. These changes are typically functional and reversible.

Biomarkers

• Blood urea nitrogen (BUN): Increases in dehydration due to reduced renal clearance of urea.
• Creatinine: May rise secondary to hemoconcentration rather than true decline in glomerular filtration.
• BUN/creatinine ratio: Elevated ratio suggests relative dehydration rather than intrinsic renal pathology.
• Estimated glomerular filtration rate (eGFR): May decrease transiently in volume depletion but typically normalizes with rehydration.

Endocrine Adaptation and Sex Hormone Modulation

Weight loss alters endocrine signaling through reduced adipose tissue mass, affecting aromatase activity and sex hormone binding globulin production. These changes influence both total and bioavailable sex hormones.

Biomarkers

• Testosterone: Reflects total androgen production but does not distinguish free from bound hormone.
• SHBG: Typically increases with weight loss, reducing free hormone availability.
• Free testosterone: Best indicator of biologically active androgen status.
• Estradiol: May decline due to reduced peripheral aromatization in adipose tissue.

Cortisol and Stress Axis Activation

Caloric restriction may activate the hypothalamic-pituitary-adrenal axis as a physiological adaptation to perceived energy scarcity. This is typically mild and adaptive rather than pathological.

Biomarkers

• Morning cortisol: Reflects baseline adrenal activity. Mild elevation may represent physiological adaptation to energy restriction.

Gallbladder Physiology and Rapid Weight Loss

Rapid weight loss increases the risk of gallstone formation through bile supersaturation with cholesterol and reduced gallbladder contractility. This leads to bile stasis, which promotes crystallization and gallstone development. The process is typically gradual and asymptomatic until biliary obstruction or inflammation occurs.

Biomarkers

• ALP (alkaline phosphatase): Primary marker of cholestatic injury. Elevates in biliary obstruction due to impaired bile flow and is one of the earliest biochemical signals of gallbladder or bile duct involvement.
• ALT and AST: Hepatocellular enzymes that may rise secondarily if there is associated liver stress or inflammation, but they are not sensitive or specific for gallstone disease itself.
• Bilirubin: Reflects impaired bile excretion. Typically increases in more advanced obstruction when bile flow is significantly impaired, often alongside symptoms such as jaundice.

Hair Loss and Telogen Effluvium

Hair shedding associated with GLP-1 therapy is most consistent with telogen effluvium, a stress-related shift in hair follicle cycling triggered by rapid weight loss and nutrient depletion.

Biomarkers

• Ferritin: Strongly associated with hair follicle activity. Low levels correlate with increased shedding risk.
• Iron studies: Assess systemic iron availability relevant to follicular function.
• Vitamin B12: Supports cellular turnover in rapidly dividing tissues.
• Folate: Required for DNA synthesis in follicular growth.
• Albumin: Reflects overall protein-energy status.
• Vitamin D: May influence follicular cycling and local immune regulation.

Literature

• Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss
• Does GLP-1 Make You Tired? Causes and Fixes
• A qualitative study of the mental health outcomes in people being treated for obesity and type 2 diabetes with glucagon-like peptide-1 receptor agonists
• The GLP-1 Aftermath: What the Science Says About Muscle Loss and Cellular Aging
• Nutritional deficiencies and muscle loss in adults with type 2 diabetes using GLP-1 receptor agonists
• Glucagon-like peptide-1 receptor agonists suppress water intake independent of effects on food intake
• Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes
• Effects of glucagon-like peptide-1 receptor agonists on male reproductive hormones, semen parameters, and metabolic outcomes
• GLP-1(7-36)-amide and Exendin-4 Stimulate the HPA Axis in Rodents and Humans
• Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases
• Predictors and Characteristics of Hair Loss Among Users of GLP‐1 Receptor Agonists

A hematocrit test (Hct) measures how much of your blood consists of red blood cells. Capillary hematocrit refers specifically to the measurement obtained using a small capillary tube — a method also called the microhematocrit technique, which requires a smaller blood sample and less time for the testing procedure. The result is expressed as a percentage, representing how much of your total blood volume is made up of red blood cells.

Blood is made of red blood cells, white blood cells, platelets, and plasma (the fluid part). Having a healthy number of red blood cells is important because they carry oxygen throughout your body.

Why is hematocrit important?

Hematocrit is often used as an indicator of the oxygen-carrying capacity of blood. It can also be used as an indicator of the health of the bone marrow where red blood cells are produced.

Hematocrit levels that are too high or too low can indicate a blood disorder, dehydration, or other medical conditions. An abnormally low hematocrit may suggest anemia, a decrease in the total amount of red blood cells, while an abnormally high hematocrit is called polycythemia.

How can I better understand my hematocrit levels?

Higher than normal hematocrit may indicate polycythemia or erythrocytosis. Causes of a high hematocrit include dehydration, low availability of oxygen (such as from smoking, high altitude, or pulmonary fibrosis).

Lower than normal hematocrit may indicate anemia or nutritional deficiencies. A low hematocrit with a low mean corpuscular volume (MCV) and a high red cell distribution width (RDW) suggests a chronic iron-deficient anemia resulting in abnormal hemoglobin synthesis. Decreased hematocrit levels could also indicate life-threatening diseases such as leukemia. Further evaluation, including a complete blood count (CBC) and medical history assessment, may be necessary to determine the underlying cause.

How can I maintain optimal hematocrit levels?

Maintaining balanced hematocrit levels involves the following steps:

Dietary Changes: Iron-rich foods work better when paired with vitamin C sources. Your body absorbs less iron if you consume caffeine and calcium with meals. Heme iron sources such as red meat, liver, poultry, fish, and seafood provide the most usable form of iron. Non-heme iron sources like beans, lentils, spinach, tofu, and fortified cereals provide plant-based iron. Vitamin B12, found in animal and dairy products, is essential for red blood cell production. Those following a vegetarian or vegan diet may need to take vitamin B12 supplements. Consuming a source of Vitamin C, like citrus fruits, bell peppers, or strawberries, alongside non-heme iron foods such as spinach or beans can significantly improve iron uptake.

Lifestyle Changes: Stay hydrated by drinking 8–12 glasses of water per day, engage in moderate exercise like brisk walking or light cycling, and avoid smoking, as it can negatively impact circulation and overall blood health. Engaging in intense physical activity, particularly endurance exercise, can stimulate the body to produce more red blood cells over time, helping improve oxygen delivery to working muscles. Stress takes a toll on blood health, as the body releases hormones that affect how blood flows and delivers oxygen, so managing stress is important for maintaining healthy hematocrit levels.

Supplementation: Supplements containing iron or B vitamins should only be taken after a confirmed deficiency is diagnosed by a doctor, as iron supplements can cause side effects like constipation, and excessive intake without a deficiency can lead to iron overload. In some cases, your physician may also recommend folate (vitamin B9) to support red blood cell production.

Where can I learn more?

• PubMed – Hematocrit
• Cleveland Clinic – Hematocrit Test
• NCBI Bookshelf – Hemoglobin and Hematocrit

DISCLAIMER: IF YOU ARE CONCERNED WITH ANY OF YOUR RESULTS, PLEASE CONSULT WITH YOUR PHYSICIAN.

Heart & Metabolic Age is a simplified, age-like estimate of your cardiometabolic health, based on two powerful signals from your bloodwork:

1. Atherogenic particle burden (how many “plaque-forming” cholesterol particles you carry)
2. Insulin sensitivity (how efficiently your body handles energy and blood fats)

It’s designed to be easy to understand, easy to track over time, and tightly focused on the health domains that drive long-term cardiovascular and metabolic risk.

The Heart & Metabolic Phenotype

To give a clearer picture than a single number alone, we first place you into a 2×2 phenotype map based on two inputs:

1) Lipid Metabolism (ApoB)

ApoB reflects the number of atherogenic (“plaque-building”) particles in your blood (including LDL and other ApoB-containing particles). In general:

• Lower ApoB = fewer atherogenic particles
• Higher ApoB = more atherogenic particles

2) Insulin Sensitivity (Triglycerides/HDL-C Ratio)

The Triglycerides-to-HDL-C ratio (Trig/HDL-C) captures two hallmarks of reduced insulin sensitivity: higher triglycerides and lower HDL-C. A lower ratio suggests better metabolic efficiency.

In general:

• Lower Trig/HDL-C = better insulin sensitivity signal
• Higher Trig/HDL-C = more insulin-resistance–associated pattern

What the 4 phenotypes mean

Your position on the map reflects one of four patterns:

• Optimal: Both ApoB and insulin sensitivity look favorable
• Lipid regulated, insulin resistant: ApoB looks favorable, but the Trig/HDL-C pattern suggests reduced insulin sensitivity
• Lipid dysregulated, insulin sensitive: insulin sensitivity looks favorable, but ApoB suggests elevated atherogenic particle burden
• Lipid dysregulated, insulin resistant: both signals suggest higher heart and metabolic risk

This map helps you understand whether your focus should be on lipids, metabolic health, or both.

How Heart & Metabolic Age is Calculated

After placing you on the 2×2 phenotype map, we translate your ApoB and Trig/HDL-C pattern into a single Heart & Metabolic score, then translate that score into an age-like number relative to your chronological age.

Younger Heart & Metabolic Age reflects a more favorable cardiometabolic profile—your markers look like those typically seen in lower-risk, younger individuals.

Older Heart & Metabolic Age suggests more room for improvement in the factors that drive cardiovascular and metabolic risk.

How to Interpret Your Heart & Metabolic Age

• Lower than your chronological age: Your ApoB and insulin-sensitivity pattern look more like what’s typical in lower-risk, younger cardiometabolic profiles.
• Higher than your chronological age: Your markers look more like patterns commonly associated with higher cardiometabolic risk, which can be a useful prompt to focus on improvements.
• Close to your chronological age: Your profile is broadly similar to others in your age range.

Just like with any health score, the most useful insight often comes from trends over time, especially if your collection conditions are consistent.

Why This Matters

Cardiometabolic health isn’t just one factor among many, it’s foundational. Atherosclerosis and insulin resistance are among the strongest predictors of long-term disease risk, and both are influenced by modifiable factors like diet, exercise, sleep, and stress.

Heart & Metabolic Age distills these complex dynamics into a single, trackable number. Instead of interpreting multiple markers in isolation, you get a clear summary of where you stand and whether you’re trending in the right direction.

Important Notes and Limitations

• This is not a diagnosis and does not replace medical care.
• Triglycerides (and therefore Trig/HDL-C) can shift with recent meals, alcohol, illness, sleep disruption, and recent intense exercise. For the cleanest comparisons, test under similar conditions each time.
• Medications and supplements (especially lipid- and glucose-related therapies) can meaningfully change these markers—often in a positive direction. This is expected and reflects real improvement.

You’re 45 years old, but is your body? That’s the question biological age tries to answer.

Your chronological age is simply how many years you’ve been alive. Your biological age looks deeper, examining patterns across your blood biomarkers to estimate whether your body more closely resembles someone younger, older, or right around your actual age.

Think of it as a health fingerprint translated into a single, trackable number.

How to Interpret Your Result

• Lower biological age: Your overall biomarker pattern looks more similar to people who are chronologically younger.
• Higher biological age: Your overall biomarker pattern looks more similar to people who are chronologically older. This can be a useful prompt to focus on areas that may be holding your health back.
• Similar to your chronological age: Your biomarker pattern is broadly similar to others in your age range, which is common.

A helpful way to think about this: biological age is a summary signal, not a diagnosis. It reflects the combined “shape” of your biomarker profile, not any single result.

Why It Matters

Biological age can help you:

• See the bigger picture across multiple body systems (metabolic, cardiovascular, inflammation, hormones, and more).
• Track trends over time, especially when you test consistently.
• Identify areas to prioritize when paired with your biomarker insights and action plan.

Here’s what makes biological age especially useful: because biomarkers respond to lifestyle, sleep, stress, nutrition, and medical care, your biological age can change. Unlike your chronological age, this number isn’t fixed.

How Is Biological Age Calculated?

There is no single lab test that directly measures “true” biological age, so models like ours learn how biomarker patterns typically vary with age across large populations, then compare your results to those patterns.

At a high level, our approach works like this:

• Training data: We trained our model using a combination of large public health datasets and internal data.
• How your score is generated: When you get results, the model compares your biomarker pattern to the patterns it learned and estimates the age your profile most closely resembles.

Biological age is calculated using a subset of available biomarkers (at least ~50% required). These include: 

Males: Hemoglobin A1C, Vitamin D (25-OH Vitamin D), ALT (Alanine Aminotransferase), Albumin, Apolipoprotein A1 (ApoA1), Apolipoprotein B (ApoB), AST (Aspartate Aminotransferase), Blood Urea Nitrogen (BUN), Calcium, Total Cholesterol, Cortisol, Creatinine, DHEA-S (Dehydroepiandrosterone Sulfate), Ferritin (iron storage), Follicle-Stimulating Hormone (FSH), HDL Cholesterol, High-Sensitivity C-Reactive Protein, Homocysteine, Iron, LDL Cholesterol, Luteinizing Hormone (LH), Prostate-Specific Antigen (PSA), Thyroid-Stimulating Hormone (TSH), Total Bilirubin, Total Protein, Triglycerides

Females: Hemoglobin A1C, Vitamin D (25-OH Vitamin D), ALT (Alanine Aminotransferase), Albumin, Apolipoprotein A1 (ApoA1), Apolipoprotein B (ApoB), AST (Aspartate Aminotransferase), Blood Urea Nitrogen (BUN), Calcium, Total Cholesterol, Cortisol, Creatinine, Ferritin (iron storage), Follicle-Stimulating Hormone (FSH), HDL Cholesterol, High-Sensitivity C-Reactive Protein, Homocysteine, Iron, LDL Cholesterol, Luteinizing Hormone (LH), Thyroid-Stimulating Hormone (TSH), Total Bilirubin, Total Protein, Triglycerides, Estradiol (Sensitive)

How Accurate Is It?

Biological age is an estimate. It is designed to be directionally meaningful and consistent over time, especially when you retest under similar conditions.

Short-term factors (illness, major sleep disruption, inflammation, medication changes, recent supplementation, training load, etc.) can temporarily shift biomarkers and influence the score. Some biomarkers can move in ways that are “health-positive” but still correlate with age trends in population data (for example, supplementation effects), which can sometimes affect the estimate.

Why Your Biological Age May Change Over Time

It’s normal for biological age to shift between tests because your biomarkers change with lifestyle, recovery, stress, and health status. Normal biological variation and lab variation exist, and the model may be updated over time as we expand training data and improve performance.

For interpretation, it’s best to focus on your trend over multiple tests, which biomarkers are driving the change, and whether changes match how you feel.

Biological Age vs. Heart & Metabolic Age

If you’ve also completed a Heart & Metabolic panel, you’ll see a second age estimate. Heart & Metabolic Age is a structured score translated into an age-like number based on the SiPhox Heart and Metabolic phenotype.

Biological Age uses a broader set of biomarkers and a machine learning approach trained on population patterns across age and sex. It is intended to reflect a more general “whole-body” biomarker aging signal rather than one specific domain.

Both are useful. Heart & Metabolic Age tells you how your cardiovascular system is holding up. Biological Age gives you a wider lens on overall aging. If you have access to both, consider them complementary views of your health.

Important Notes

• Biological age is not a medical diagnosis and should not be used alone to diagnose or treat any condition.
• It does not capture every factor that influences aging (genetics, imaging findings, fitness, body composition, sleep quality, medical history, and more).